financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher
Jun 12, 2024 5:59 AM

08:37 AM EDT, 06/12/2024 (MT Newswires) -- XOMA ( XOMA ) said Wednesday it has received an $8.1 million milestone payment related to the sale by Day One Biopharmaceuticals ( DAWN ) of its Priority Review Voucher to an undisclosed buyer for $108 million.

XOMA ( XOMA ) said it received the payment from Viracta Therapeutics ( VIRX ) , to which it paid $13.5 million in March 2021 to acquire up to $54 million in potential milestones and mid-single digit royalties associated with cancer drug Ojemda and economics associated with vosaroxin.

XOMA ( XOMA ) Chief Executive Owen Hughes said the company expects future royalties on Ojemda to add to a portfolio of royalty receipts that will support the company's free cash flow generation.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Decliners
Top Premarket Decliners
Jul 17, 2024
08:12 AM EDT, 07/17/2024 (MT Newswires) -- ASLAN Pharmaceuticals ( ASLN ) shares plunged 50% in recent Wednesday premarket activity, after saying its ASLAN Pharmaceuticals Pte sole operating unit submitted a voluntary liquidation application. Five Below ( FIVE ) shares were down 14%, a day after issuing a lower-than-expected fiscal Q2 diluted income per common share and sales outlook. Comparable...
 Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
Jul 17, 2024
On Wednesday, Johnson & Johnson ( JNJ )  reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion. Operational growth was 6.6%, and adjusted operational growth was 6.5%. The adjusted operational growth excluding COVID-19 Vaccine was 7.1%. Also Read: Johnson &...
 --B. Riley Adjusts Lindblad Expeditions Holdings' PT to $15 From $13, Maintains Buy Rating
--B. Riley Adjusts Lindblad Expeditions Holdings' PT to $15 From $13, Maintains Buy Rating
Jul 17, 2024
08:12 AM EDT, 07/17/2024 (MT Newswires) -- Price: 10.67, Change: -0.05, Percent Change: -0.47 ...
 Market Chatter: TotalEnergies Divests 10% Stake in Nigerian Oil Assets to Chappal Energies for $860 Million
Market Chatter: TotalEnergies Divests 10% Stake in Nigerian Oil Assets to Chappal Energies for $860 Million
Jul 17, 2024
08:11 AM EDT, 07/17/2024 (MT Newswires) -- TotalEnergies (TTE) agreed to sell its 10% stake in Nigerian oil and gas assets to Chappal Energies for $860 million, concluding a two-year sale process, Bloomberg reported Wednesday, citing a statement. The acquisition includes a 10% interest in 15 oil mining leases and the Forcados and Bonny export terminals. TotalEnergies affiliate or a...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved